FDA again turns back Capricor Duchenne cell therapy
BioPharma DiveGwendolyn WuNovember 21, 2026
In an unusual statement, the FDA accused Capricor of serious data integrity violations that compromised its study findings and led to deramiocel s second rejection since 2025.
